Capital International Investors Invests $43.67 Million in Heartflow, Inc. $HTFL

Capital International Investors purchased a new stake in shares of Heartflow, Inc. (NASDAQ:HTFL) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 1,297,423 shares of the company’s stock, valued at approximately $43,671,000. Capital International Investors owned 1.56% of Heartflow as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also bought and sold shares of the stock. Baillie Gifford & Co. acquired a new position in shares of Heartflow during the 3rd quarter valued at $101,182,000. TD Asset Management Inc acquired a new stake in shares of Heartflow in the third quarter valued at $2,692,000. New York State Common Retirement Fund bought a new position in Heartflow during the third quarter valued at about $4,015,000. Artisan Partners Limited Partnership acquired a new position in Heartflow during the third quarter worth about $16,817,000. Finally, JPMorgan Chase & Co. bought a new stake in Heartflow in the third quarter worth about $13,887,000.

Heartflow Price Performance

Shares of HTFL stock opened at $20.79 on Friday. Heartflow, Inc. has a fifty-two week low of $20.13 and a fifty-two week high of $41.22. The stock’s 50-day moving average is $27.83 and its two-hundred day moving average is $30.76. The firm has a market cap of $1.77 billion and a P/E ratio of -11.49.

Insider Buying and Selling

In other Heartflow news, insider Campbell Rogers sold 65,153 shares of the business’s stock in a transaction on Thursday, February 12th. The shares were sold at an average price of $24.49, for a total transaction of $1,595,596.97. Following the completion of the transaction, the insider owned 76,034 shares of the company’s stock, valued at $1,862,072.66. The trade was a 46.15% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO John C.M. Farquhar sold 12,837 shares of the business’s stock in a transaction dated Tuesday, March 10th. The stock was sold at an average price of $22.66, for a total value of $290,886.42. Following the transaction, the chief executive officer directly owned 581,450 shares of the company’s stock, valued at $13,175,657. This represents a 2.16% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 2,117,674 shares of company stock valued at $59,052,646.

Wall Street Analysts Forecast Growth

HTFL has been the topic of a number of research reports. JPMorgan Chase & Co. boosted their target price on shares of Heartflow from $36.00 to $40.00 and gave the stock an “overweight” rating in a report on Thursday, November 13th. Wells Fargo & Company assumed coverage on shares of Heartflow in a report on Wednesday, January 28th. They set an “overweight” rating and a $38.00 target price for the company. Stifel Nicolaus upped their price target on Heartflow from $35.00 to $40.00 and gave the company a “buy” rating in a report on Thursday, November 13th. Canaccord Genuity Group reiterated a “buy” rating and set a $40.00 price objective on shares of Heartflow in a research report on Monday. Finally, Weiss Ratings restated a “sell (d)” rating on shares of Heartflow in a report on Monday, December 29th. Five research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $38.50.

Heartflow Company Profile

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.